Quinazolines

Results: 237



#Item
11HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GILOTRIF safely and effectively. See full prescribing information for GILOTRIF. ®

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GILOTRIF safely and effectively. See full prescribing information for GILOTRIF. ®

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2016-04-18 15:38:46
12erlotinib lung cancer, erlotinib tarceva erlotinib brand name, gemcitabine erlotinib maintenance. erlotinib dialogo farmaci erlotinib hydrochloride, erlotinib pharmacokinetics, erlotinib lung approval, dasatinib and erlo

erlotinib lung cancer, erlotinib tarceva erlotinib brand name, gemcitabine erlotinib maintenance. erlotinib dialogo farmaci erlotinib hydrochloride, erlotinib pharmacokinetics, erlotinib lung approval, dasatinib and erlo

Add to Reading List

Source URL: www.naturaldiamondcompany.com

Language: English - Date: 2016-06-19 10:30:14
13erlotinib smpc erlotinib egfr, erlotinib hydrochloride cancer treatment erlotinib, tarceva erlotinib erlotinib dosing erlotinib tarceva fda erlotinib supplemental, lung ca erlotinib. clarke g and erlotinib

erlotinib smpc erlotinib egfr, erlotinib hydrochloride cancer treatment erlotinib, tarceva erlotinib erlotinib dosing erlotinib tarceva fda erlotinib supplemental, lung ca erlotinib. clarke g and erlotinib

Add to Reading List

Source URL: pulseseismic.com

Language: English - Date: 2016-06-18 06:46:08
14iressa breast cancer. cancer iressa iressa filingiressa and nsclc and squamous cell iressa and isel trial, iressa trials. binding mode iressa iressa manufacturer, iressa docking. iressa results iressa adverse even

iressa breast cancer. cancer iressa iressa filingiressa and nsclc and squamous cell iressa and isel trial, iressa trials. binding mode iressa iressa manufacturer, iressa docking. iressa results iressa adverse even

Add to Reading List

Source URL: pulseseismic.com

Language: English - Date: 2016-06-17 18:24:11
15Microsoft PowerPoint - cr_data_submissions_19338_new_figure_6_for_19338 [Read-Only]

Microsoft PowerPoint - cr_data_submissions_19338_new_figure_6_for_19338 [Read-Only]

Add to Reading List

Source URL: michorlab.dfci.harvard.edu

Language: English - Date: 2015-08-04 10:55:49
16Optimization of Dosing for EGFR-Mutant Non−Small Cell Lung Cancer with Evolutionary Cancer Modeling Juliann Chmielecki, et al. Sci Transl Med 3, 90ra59 (2011); DOI: scitranslmed

Optimization of Dosing for EGFR-Mutant Non−Small Cell Lung Cancer with Evolutionary Cancer Modeling Juliann Chmielecki, et al. Sci Transl Med 3, 90ra59 (2011); DOI: scitranslmed

Add to Reading List

Source URL: michorlab.dfci.harvard.edu

Language: English - Date: 2011-08-23 09:57:30
17Published Ahead of Print on February 11, 2013 asJCOThe latest version is at http://jco.ascopubs.org/cgi/doiJCOJOURNAL OF CLINICAL ONCOLOGY  R E V I E W

Published Ahead of Print on February 11, 2013 asJCOThe latest version is at http://jco.ascopubs.org/cgi/doiJCOJOURNAL OF CLINICAL ONCOLOGY R E V I E W

Add to Reading List

Source URL: michorlab.dfci.harvard.edu

Language: English - Date: 2013-02-12 09:06:44
18ORIGINAL ARTICLE  Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer Jasmine Foo, PhD,* Juliann Chmielecki, PhD,† William Pao

ORIGINAL ARTICLE Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer Jasmine Foo, PhD,* Juliann Chmielecki, PhD,† William Pao

Add to Reading List

Source URL: michorlab.dfci.harvard.edu

Language: English - Date: 2012-10-16 11:34:15
19

PDF Document

Add to Reading List

Source URL: michorlab.dfci.harvard.edu

Language: English - Date: 2011-12-13 10:38:22
20Downloaded from genome.cshlp.org on October 7, Published by Cold Spring Harbor Laboratory Press  Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell

Downloaded from genome.cshlp.org on October 7, Published by Cold Spring Harbor Laboratory Press Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell

Add to Reading List

Source URL: michorlab.dfci.harvard.edu

Language: English - Date: 2013-10-07 10:43:04